Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Study ID
NCT06096974
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • YL-17231 — DRUG
    YL-17231 will be administered orally once daily in a continuous regimen

Study Details

This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.

Key Dates

Start date
Oct 24, 2023
Status verified
Apr 2025
Primary completion
Oct 31, 2025
Completion
Apr 30, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation and Expansion
    Dose escalation of YL-17231 to determine maximum tolerated dose.Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of YL-17231 to recommend Phase 2 regimens

Primary Outcome Measure

Occurrence of dose limiting toxicities (DLTs) [ Time Frame: The first cycle (21 days) ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
The Lindner Center for Research & Education at The Christ HospitalCincinnatiOhio45219
Alexander Starodub
(513) 321-4333
MD Anderson Cancer CenterHoustonTexas77030
David Hong, PhD
(713) 563-1930
Huntsman Cancer Institute and Hospital, University of UtahSalt Lake CityUtah84112
Ignacio Garrido-Laguna
(801) 585-0255

Find similar trials in Cincinnati, OH

By research site
The Lindner Center for Research & Education at The Christ Hospital· Cincinnati, OHMD Anderson Cancer Center· Houston, TXHuntsman Cancer Institute and Hospital, University of Utah· Salt Lake City, UT

Related Studies